Browsing by Author Brahmbhatt, Himanshu

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 5 of 5
Issue DateTitleAuthor(s)Citation
2016Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancerBoyer, Michael; Clarke, Stephen; Kao, Steven; Pavlakis, Nick; Reid, Glen; van Zandwijk, Nico; Brahmbhatt, Himanshu; MacDiarmid, Jennifer; Central Clinical School: Medicine; Northern Clinical School: Kolling Institute; Concord Clinical School: Medicine; Northern Clinical School: Medicine; Concord Clinical School: Medicine; Concord Clinical School: ANZAC Research InstituteClinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer, Epigenomics, vol.8, 8, 2016,pp 1079-1085
2015First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastomaSimes, Robert John; Brahmbhatt, Himanshu; Gan, Hui K.; Lickliter, Jason D; MacDiarmid, Jennifer; Rosenthal, Mark; Scott, Andrew M.; Solomon, Benjamin; Whittle, James R; NH&MRC Clinical Trials CentreFirst in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma, Journal of Clinical Neuroscience, vol.22, 12, 2015,pp 1889-1894
2015microRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinomaClarke, Stephen; Feeney, Alex L; Gill, Anthony; Glover, Anthony; Ip, Julian; Kim, Edward; Reid, Glen; Robinson, Bruce; Sidhu, Stan; Zhao, Jing; Brahmbhatt, Himanshu; MacDiarmid, Jennifer; Mugridge, Nancy; Soon, Patsy; Weiss, Jocelyn; Northern Clinical School: Kolling Institute; Northern Clinical School: Kolling Institute; Northern Clinical School: Pathology; Northern Clinical School: Kolling Institute; Northern Clinical School: Kolling Institute; Northern Clinical School: Kolling Institute; Concord Clinical School: Medicine; Northern Clinical School: Medicine; Northern Clinical School: Kolling Institute; Northern Clinical School: Kolling InstitutemicroRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma, Oncotarget, vol.6, 34, 2015,pp 36675-36688
2015miR-193a-3p is a potential tumor suppressor in malignant pleural mesotheliomaCooper, Wendy Anne; Edelman, John (James); Hanh, Jacky; Kao, Steven; Kirschner, Michaela; Linton, Anthony; Reid, Glen; Vallely, Michael; van Zandwijk, Nico; Amaro-Mugridge, Nancy; Brahmbhatt, Himanshu; Cheng, YuenYee; Klebe, Sonja; Lin, Ruby C. Y.; MacDiarmid, Jennifer; McCaughan, Brian; Weiss, Jocelyn; Williams, Marissa; Wright, Casey; Central Clinical School: Medicine; Central Clinical School: Surgery; Concord Clinical School: Asbestos Disease Research Institute; Concord Clinical School: Medicine; Concord Clinical School: Medicine; Concord Clinical School: Medicine; Concord Clinical School: Medicine; Central Clinical School: Surgery; Concord Clinical School: ANZAC Research InstitutemiR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma, Oncotarget, vol.6, 27, 2015,pp 23480-23495
2017Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation studyBailey, Dale; Boyer, Michael; Chrzanowska, Agata; Clarke, Stephen; Cooper, Wendy Anne; Fulham, Michael; Huynh, Yen; Kao, Steven; Kritharides, Leonard; Linton, Anthony; Pavlakis, Nick; Reid, Glen; van Zandwijk, Nico; Brahmbhatt, Himanshu; MacDiarmid, Jennifer; Pattison, Scott; Ridley, Lloyd; Medical Imaging and Radiation Sciences; Central Clinical School: Medicine; School of Public Health: Public Health; Northern Clinical School: Kolling Institute; Central Clinical School: Medicine; Information Technologies; Concord Clinical School: Medicine; Central Clinical School: Medicine; Concord Clinical School: ANZAC Research Institute; Concord Clinical School: Medicine; Northern Clinical School: Medicine; Concord Clinical School: Medicine; Concord Clinical School: MedicineSafety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation study, The Lancet Oncology, vol.18, 10, 2017,pp 1386-1396